Lexeo Therapeutics (LXEO) Total Current Liabilities (2022 - 2026)

Lexeo Therapeutics' Total Current Liabilities history runs 5 years deep, the most recent figure standing at $14.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 53.97% year-over-year to $14.2 million; the TTM figure through Mar 2026 stood at $14.2 million (down 53.97% YoY), while the FY2025 annual figure was $16.8 million, down 26.43% from the prior year.
• Total Current Liabilities came in at $14.2 million for Q1 2026 at Lexeo Therapeutics, down from $16.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $31.6 million in Q2 2025 to a low of $14.2 million in Q1 2026.
• A 5-year average of $21.3 million and a median of $20.3 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 67.36% in 2025 and slumped 53.97% in 2026, its largest moves.
• Lexeo Therapeutics' Total Current Liabilities stood at $14.3 million in 2022, then rose by 20.14% to $17.2 million in 2023, then surged by 32.53% to $22.8 million in 2024, then slipped by 26.43% to $16.8 million in 2025, then declined by 15.58% to $14.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $14.2 million, $16.8 million, and $17.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison